Goslings W R, Prodeus A P, Streilein J W, Carroll M C, Jager M J, Taylor A W
Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114, USA.
Invest Ophthalmol Vis Sci. 1998 May;39(6):989-95.
Aqueous humor inhibits activation of the classic complement pathway; however, the mechanism of this inhibition is unknown. We have examined at the molecular level potential factors responsible for the inhibition, and we have tried to determine where in the complement pathway the inhibition takes place.
Fresh rabbit aqueous humor was size fractionated by centrifuge concentrators and by size exclusion column chromatography, and each fraction was assayed for inhibition of the classic complement pathway in a standard CH50 hemolytic assay. Fractions with inhibitory activity were assayed for protein and the presence of ascorbic acid and were subjected to heat treatment. To identify where in the pathway the inhibitor(s) function, the expression of activated complement components bound to the surface of antibody-coated erythrocytes was analyzed by flow cytometry using fluorescein isothiocyanate-labeled antibodies to specific complement components. In addition, hemolytic assays were performed for the function of individual complement components.
The most potent inhibition of the classic pathway was in a fraction of aqueous humor of less than 1.3 kDa. The inhibitory activity in the fraction was unassociated with detectable protein or ascorbic acid, and it remained present after heat treatment. The functional analysis through flow cytometry and hemolytic assays for individual complement components showed that the inhibitor in the less than 1.3-kDa fraction caused a blockade in the complement pathway at the level of C1q.
The aqueous humor contains a unique potent anticomplementary factor that has a molecular weight less than 1.3 kDa. This heat-stable inhibitory factor inhibits the classic pathway at the level of C1q. These results imply that within the eye the complement pathway is inhibited at the earliest steps of its initiation. Such inhibition would prevent production of complement products that mediate inflammation and chemotaxis of inflammatory cells. Therefore, as part of the adaptation of immune privilege, the ocular microenvironment is protected from inflammation induced by antigen-antibody complexes.
房水可抑制经典补体途径的激活;然而,这种抑制作用的机制尚不清楚。我们在分子水平上研究了负责这种抑制作用的潜在因素,并试图确定补体途径中抑制作用发生的位置。
用离心浓缩器和尺寸排阻柱色谱法对新鲜兔房水进行尺寸分级,然后在标准CH50溶血试验中检测每个级分对经典补体途径的抑制作用。对具有抑制活性的级分进行蛋白质、抗坏血酸检测,并进行热处理。为了确定抑制剂在补体途径中的作用位置,使用针对特定补体成分的异硫氰酸荧光素标记抗体,通过流式细胞术分析结合在抗体包被红细胞表面的活化补体成分的表达。此外,还对单个补体成分的功能进行了溶血试验。
对经典途径的最强抑制作用存在于房水小于1.3 kDa的级分中。该级分中的抑制活性与可检测到的蛋白质或抗坏血酸无关,并且热处理后仍存在。通过流式细胞术和单个补体成分溶血试验进行的功能分析表明,小于1.3 kDa级分中的抑制剂在C1q水平阻断了补体途径。
房水中含有一种独特的强效抗补体因子,其分子量小于1.3 kDa。这种热稳定的抑制因子在C1q水平抑制经典途径。这些结果表明,在眼内,补体途径在其启动的最早步骤就受到抑制。这种抑制作用将阻止介导炎症和炎性细胞趋化的补体产物的产生。因此,作为免疫赦免适应的一部分,眼部微环境可免受抗原-抗体复合物诱导的炎症影响。